JAZZ PHARMACEUTICALS FRANCE

Recent advancements in HCC and BTC treatment include targeted therapy combinations like atezolizumab plus bevacizumab for HCC and durvalumab with gemcitabine and cisplatin for BTC, improving survival outcomes. Liquid biopsies and precision medicine are also transforming early detection and treatment options.

FDA approves Avadel's Lumryz for narcolepsy in children aged 7 and older, offering a once-nightly treatment option. Lumryz, already approved for adults, is superior to Jazz Pharmaceutical's Xyrem and Xywav due to its dosing regimen, which does not require middle-of-the-night administration.

Study on MM treatment decision-making highlights QoL, duration of response, and side effects as top attributes for patients, care partners, and physicians. Differences in preferences and trade-offs underscore the importance of shared decision-making (SDM) to align treatment plans with patient values and improve outcomes.

Lurbinectedin plus atezolizumab improved survival outcomes in extensive-stage small cell lung cancer patients, prompting a planned sNDA submission for first-line maintenance therapy by 2025.

Bio-pharma advances in endocrinology, dermatology, cardiovascular, oncology, rare diseases, pulmonology, gastroenterology, and neurology highlight promising therapies like Eli Lilly’s orforglipron, Amgen’s MariTide, Novo Nordisk’s oral semaglutide, Johnson & Johnson’s JNJ-2113, Sanofi’s amlitelimab, Ionis’s olezarsen, BridgeBio’s acoramidis, NewAmsterdam Pharma’s obicetrapib, Jazz Pharmaceuticals’ zanidatamab, Syndax’s revumenib, Merus’ zenocutuzumab, Johnson & Johnson’s nipocalimab, Novo Nordisk’s Mim8, Solid Biosciences’ SGT-003, Merck’s sotatercept, Johnson & Johnson’s Tremfya, and Crossject’s Zepizure, with analyses including clinical data, revenue forecasts, and expected launch dates.

Jazz Pharmaceuticals' Zepzelca (lurbinectedin) plus Roche's Tecentriq (atezolizumab) showed significant improvement in overall and progression-free survival in extensive-stage small cell lung cancer (SCLC) maintenance treatment, with safety consistent with known profiles. Jazz plans to submit a supplemental new drug application for this combination in the first half of 2025.

Zepzelca (lurbinectedin) combined with Tecentriq (atezolizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in extensive-stage small cell lung cancer (ES-SCLC) patients compared to Tecentriq alone in the Phase III IMforte trial. The combination, well-tolerated, showed no new safety signals and is planned for FDA submission as a first-line maintenance treatment for ES-SCLC in 2025.

Cannabis's move to Schedule III of the Controlled Substances Act will remove barriers for pharmaceutical companies to develop cannabis-based drugs, unlocking a $2 trillion market. This shift will favor pharma companies over state-level cannabis businesses, as the latter lack the resources for FDA approval. Pharmaceutical companies are already patenting solutions to the 'whole-plant' problem, positioning them to dominate the federally regulated market for cannabis-based prescription drugs.